Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5632 in Healthy Subjects
NCT06732154Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dyslipidemia comparing HRS-5632 with Placebo (2 arms). Primary endpoint: Adverse Events. Started Dec 2024; status: completed.
02
Drugs
HRS-5632
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06732154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732154.